Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed 14 enrolled Michaela Liedtke Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

To assess if amrubicin is safe and useful for patients with multiple myeloma requiring additional treatment.

Evaluation	Drug	Modality	Dose	Route
Subject	Amrubicin	Small molecule	40 mg/m2	Intravenous
Subject	Amrubicin	Small molecule	60 mg/m2	Intravenous
Subject	Amrubicin	Small molecule	80 mg/m2	Intravenous
Background	Aspirin	Small molecule	81 mg	Oral
Background	Aspirin	Small molecule	325 mg	Oral
Background	Dexamethasone	Small molecule	40 mg	Oral
Background	Lenalidomide	Other / unclassified	10 mg	Oral
Background	Lenalidomide	Other / unclassified	15 mg	Oral
Background	Pegfilgrastim	Protein / enzyme biologic	6 mg	Subcutaneous